688321 Shenzhen Chipscreen Biosciences
- 21.02
- -2.15-9.28%
Shenzhen Chipscreen Biosciences News
Demonstration analysis report on the issuance of A-shares to specific targets by Shenzhen Microchip Biotechnology Co., Ltd. in 2024
An indicative announcement on the disclosure of plans to issue A-shares to specific targets in 2024
Feasibility analysis report on the use of funds raised by Shenzhen Microchip Biotechnology Co., Ltd. by issuing A-shares to specific targets in 2024
Announcement on the issuance of A-shares to specific targets without providing financial support or compensation to investors directly or through stakeholders participating in the subscription
Shenzhen Microchip Biotechnology Co., Ltd.\'s plan to issue A-shares to specific targets in 2024
Microchip Biotech: Announcement on convertible debt-to-equity conversion results and share changes
Announcement on the implementation of share repurchase cancellation and share changes
Announcement on clarifying the purpose of share repurchase
Announcement on the implementation results of share repurchase
Announcement on the progress of the repurchase of company shares through centralized bidding transactions
Announcement on the 2023 Profit Distribution Plan
Announcement on the first repurchase of company shares through centralized bidding
Announcement on the progress of the repurchase of company shares through centralized bidding transactions
Repurchase report on the repurchase of company shares through centralized bidding transactions
Announcement on the shareholding status of the top ten shareholders and the top ten shareholders with unlimited sale conditions in the share repurchase event
Announcement on promoting the company\'s plan to “improve quality, increase efficiency and increase returns” and repurchase the company\'s shares through centralized bidding transactions
Announcement on qualifying conditions for the second vesting period of the 2021 Restricted Stock Incentive Plan and abolishing this part of the restricted stock
Legal opinion of Shanghai Tongli Law Firm on matters relating to the second vesting period of the Microchip Biotech 2021 Restricted Stock Incentive Plan, the second exercise period of the 2021 Stock Value-added Incentive Plan, and the abolition of certain
Announcement on whether the second exercise period of the 2021 Stock Value-added Rights Incentive Plan satisfies the conditions of exercise and abolishes this portion of the stock value-added rights
Announcement on the proposed buyback and the company\'s action plan to “improve quality, increase efficiency and focus on return”
Analysis
Price Target
No Data
No Data